Irie K, Tokuda H, Hagiwara N, Koshimizu K, Hayashi H, Murao S, Ito Y
Int J Cancer. 1985 Oct 15;36(4):485-8. doi: 10.1002/ijc.2910360412.
New derivatives of (-)-indolactam V (Fig. 1), which have the basic ring-structure of teleocidins without the monoterpenoid moiety, were prepared and their Epstein-Barr virus early antigen (EBV-EA)-inducing activity was tested. (-)-14-O-Alkyl indolactam Vs (2 and 3) showed little induction of EBV-EA, while (-)-14-dehydroxyindolactam V (4) and (-)-14-chloroindolactam V (5) proved to be potent EBV-EA inducers, though their activities (EC50) were about 10 times weaker than that of (-)-indolactam V (1). These results indicate that the hydroxyl group at C-14 is not indispensable for EBV-EA induction and can be replaced. The activities (EC50) of (-)-1-N-methyl, (-)-1-N-ethyl, and (-)-1-N-butyl indolactam V (10, 11, and 12) were about 5 times weaker than that of (-)-indolactam V (1), while (-)-1-N-hexyl and (-)-1-N-octyl indolactam V (13 and 14) were even less active, suggesting that the free imino group of the indole ring in (-)-indolactam V (1) plays an important role in the activity, and that the activity cannot be enhanced by alkylation at the N-1 position of (-)-indolactam V (1).
制备了(-)-吲哚内酰胺V(图1)的新衍生物,其具有无单萜部分的远侧杀菌素的基本环结构,并测试了它们诱导爱泼斯坦-巴尔病毒早期抗原(EBV-EA)的活性。(-)-14-O-烷基吲哚内酰胺V(2和3)几乎不诱导EBV-EA,而(-)-14-脱羟基吲哚内酰胺V(4)和(-)-14-氯吲哚内酰胺V(5)被证明是有效的EBV-EA诱导剂,尽管它们的活性(EC50)比(-)-吲哚内酰胺V(1)弱约10倍。这些结果表明,C-14位的羟基对于EBV-EA诱导不是必不可少的,可以被取代。(-)-1-N-甲基、(-)-1-N-乙基和(-)-1-N-丁基吲哚内酰胺V(10、11和12)的活性(EC50)比(-)-吲哚内酰胺V(1)弱约5倍,而(-)-1-N-己基和(-)-1-N-辛基吲哚内酰胺V(13和14)的活性甚至更低,这表明(-)-吲哚内酰胺V(1)中吲哚环的游离亚氨基在活性中起重要作用,并且在(-)-吲哚内酰胺V(1)的N-1位进行烷基化不能增强活性。